We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-4.54%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$487M
AUM Growth
+$94.7M
Cap. Flow
+$118M
Cap. Flow %
24.18%
Top 10 Hldgs %
60.21%
Holding
43
New
8
Increased
15
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
TXMD icon
TherapeuticsMD
TXMD
+$20.3M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$17.6M
3
TRVN
Trevena, Inc.
TRVN
+$17.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$16.1M
5
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.9M

Top Sells

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$18.2M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$11.2M
3
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$7.57M
4
PLXP
PLx Pharma Inc. Common Stock
PLXP
+$2.59M
5
PDLI
PDL BioPharma, Inc.
PDLI
+$2.16M

Sector Composition

Rank Sector Weight
1 Healthcare 81.16%
2 Technology 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCRX
26
DELISTED
Ocera Therapeutics, Inc.
OCRX
$4.12M 0.85%
1,963,777
– –
DERM
27
DELISTED
Dermira, Inc.
DERM
$3.46M 0.71%
114,080
-565,323
-83% -$18.2M
BCRX icon
28
CALL
BioCryst Pharmaceuticals
BCRX
$2.28B
$3.17M 0.65%
+500,000
New +$2.6M
ALIM
29
DELISTED
Alimera Sciences
ALIM
$2.48M 0.51%
152,912
-22,953
-13% -$420K
TENX icon
30
Tenax Therapeutics
TENX
$363M
$2.16M 0.44%
35
– –
ATXS
31
DELISTED
Astria Therapeutics
ATXS
$2.01M 0.41%
9,276
+5,109
+123% +$1.25M
ALNY icon
32
Alnylam Pharmaceuticals
ALNY
$27.5B
$1.94M 0.4%
+51,935
New +$2.17M
ARDM
33
DELISTED
Aradigm Corp Common Stock
ARDM
$1.27M 0.26%
791,870
-211,092
-21% -$925K
STRM
34
DELISTED
Streamline Health Solutions
STRM
$190K 0.04%
10,107
– –
ISEE
35
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$34K 0.01%
7,100
+3,700
+109% +$110K
ARDX icon
36
Ardelyx
ARDX
$1.22B
– –
-15,000
Closed -$194K
MCRB icon
37
Seres Therapeutics
MCRB
$46.8M
– –
-6,000
Closed -$1.48M
MCRB icon
38
PUT
Seres Therapeutics
MCRB
$46.8M
– –
-6,000
Closed -$1.48M
NVAX icon
39
CALL
Novavax
NVAX
$1.2B
– –
-20,460
Closed -$851K
PLXP
40
DELISTED
PLx Pharma Inc. Common Stock
PLXP
– –
-22,366
Closed -$2.59M
GWPH
41
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-23,800
Closed -$3.16M
TTPH
42
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-22,619
Closed -$1.73M
PDLI
43
DELISTED
PDL BioPharma, Inc.
PDLI
– –
-645,000
Closed -$2.16M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2016 Portfolio in Review

As of Q4 2016, Great Point Partners held 43 positions worth $487M, up 24% from $392M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Great Point Partners deployed $118M of net new capital in Q4 2016, opening 8 new positions and adding to 15 existing holdings. Its largest new stake was TherapeuticsMD: 65,520 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 77% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Dermira, Inc., an estimated $18.2M trimmed.

  • Great Point Partners's largest Q4 2016 buy was TherapeuticsMD: 65,520 shares worth $18.9M.
  • Great Point Partners added most to Neurocrine Biosciences in Q4 2016, an estimated $16.1M increase.
  • Great Point Partners's biggest Q4 2016 reduction was Dermira, Inc., cutting an estimated $18.2M.
  • Great Point Partners fully exited PLx Pharma Inc. Common Stock in Q4 2016, selling an estimated $2.59M.
  • Great Point Partners's ten largest holdings make up 60% of its $487M portfolio in Q4 2016.
  • Great Point Partners opened 8 new positions and closed 8 in Q4 2016.
  • Great Point Partners's portfolio value rose 24% quarter-over-quarter to $487M.

Based on Great Point Partners's 13F filing for Q4 2016, filed 14 Feb 2017.